130 related articles for article (PubMed ID: 28639741)
1. The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study.
Gregersen H; Vangsted AJ; Abildgaard N; Andersen NF; Pedersen RS; Frølund UC; Helleberg C; Broch B; Pedersen PT; Gimsing P; Klausen TW
Cancer Med; 2017 Jul; 6(7):1807-1816. PubMed ID: 28639741
[TBL] [Abstract][Full Text] [Related]
2. The impact of comorbidity on mortality in Danish sarcoma patients from 2000-2013: A nationwide population-based multicentre study.
Raedkjaer M; Maretty-Kongstad K; Baad-Hansen T; Jørgensen PH; Safwat A; Vedsted P; Petersen MM; Hovgaard T; Nymark T; Keller J
PLoS One; 2018; 13(6):e0198933. PubMed ID: 29889880
[TBL] [Abstract][Full Text] [Related]
3. Survival trends in elderly myeloma patients.
Jones A; Bowcock S; Rachet B
Eur J Haematol; 2021 Jan; 106(1):126-131. PubMed ID: 33037667
[TBL] [Abstract][Full Text] [Related]
4. Prognostic consequences of implementing cancer patient pathways in Denmark: a comparative cohort study of symptomatic cancer patients in primary care.
Jensen H; Tørring ML; Vedsted P
BMC Cancer; 2017 Sep; 17(1):627. PubMed ID: 28874125
[TBL] [Abstract][Full Text] [Related]
5. Comorbidity among Danish lung cancer patients before and after initial cancer diagnosis.
Gouliaev A; Hilberg O; Christensen NL; Rasmussen T; Ibsen R; Løkke A
Eur Clin Respir J; 2020 Dec; 8(1):1861579. PubMed ID: 33425261
[No Abstract] [Full Text] [Related]
6. Sex differences in outcomes in multiple myeloma.
Derman BA; Langerman SS; Maric M; Jakubowiak A; Zhang W; Chiu BC
Br J Haematol; 2021 Feb; 192(3):e66-e69. PubMed ID: 33216365
[No Abstract] [Full Text] [Related]
7. Routes to diagnosis and the association with the prognosis in patients with cancer - A nationwide register-based cohort study in Denmark.
Danckert B; Falborg AZ; Christensen NL; Frederiksen H; Lyratzopoulos G; McPhail S; Ryg J; Vedsted P; Thomsen LA; Jensen H
Cancer Epidemiol; 2021 Oct; 74():101983. PubMed ID: 34352658
[TBL] [Abstract][Full Text] [Related]
8. Comorbidity indices for prognostic evaluation in multiple myeloma: a comprehensive evaluation of the Revised Myeloma Comorbidity Index and other comorbidity indices with pro- and retrospective applications.
Schoeller K; Ihorst G; Reinhardt H; Holler M; Scheubeck S; Herget G; Wäsch R; Engelhardt M
Haematologica; 2024 Apr; 109(4):1279-1284. PubMed ID: 38031759
[No Abstract] [Full Text] [Related]
9. Multiple Myeloma in Young Patients: A Scoping Review.
Steinbach M; Neupane K; Aziz M; Lee-Smith W; Julian K; Godara A; McClune B; Kelkar AH; Sborov D; Mohyuddin GR
Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):15-22. PubMed ID: 37722944
[TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Dimopoulos MA; Moreau P; Terpos E; Mateos MV; Zweegman S; Cook G; Delforge M; Hájek R; Schjesvold F; Cavo M; Goldschmidt H; Facon T; Einsele H; Boccadoro M; San-Miguel J; Sonneveld P; Mey U; ;
Ann Oncol; 2021 Mar; 32(3):309-322. PubMed ID: 33549387
[No Abstract] [Full Text] [Related]
11. Quantitative risk factor analysis of prior disease condition and socioeconomic status with the multiple myeloma development: nationwide cohort study.
Choi S; Kim E; Jung J; Park SS; Min CK; Han S
Sci Rep; 2024 Feb; 14(1):4885. PubMed ID: 38418448
[TBL] [Abstract][Full Text] [Related]
12. Exploring Indicators of Vulnerability in Older Adults With Newly Diagnosed Multiple Myeloma.
Wildes TM
JCO Clin Cancer Inform; 2024 Mar; 8():e2400013. PubMed ID: 38507666
[TBL] [Abstract][Full Text] [Related]
13. Mortality in patients with lymphoid malignancies and multiple myeloma was stable upon and during the COVID-19 pandemic: A population-based, nation-wide study.
Faitová T; Brieghel C; Eriksson F; Niemann CU
Hemasphere; 2024 Mar; 8(3):e57. PubMed ID: 38505245
[No Abstract] [Full Text] [Related]
14. Natural history of t(11;14) multiple myeloma.
Lakshman A; Alhaj Moustafa M; Rajkumar SV; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Leung N; Go RS; Lin Y; Kourelis TV; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
Leukemia; 2018 Jan; 32(1):131-138. PubMed ID: 28655925
[TBL] [Abstract][Full Text] [Related]
15. Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma.
Laganà A; Perumal D; Melnekoff D; Readhead B; Kidd BA; Leshchenko V; Kuo PY; Keats J; DeRome M; Yesil J; Auclair D; Lonial S; Chari A; Cho HJ; Barlogie B; Jagannath S; Dudley JT; Parekh S
Leukemia; 2018 Jan; 32(1):120-130. PubMed ID: 28642592
[TBL] [Abstract][Full Text] [Related]
16. Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone.
Vogl DT; Delforge M; Song K; Guo S; Gibson CJ; Ervin-Haynes A; Facon T
Leuk Lymphoma; 2018 Feb; 59(2):398-405. PubMed ID: 28641472
[TBL] [Abstract][Full Text] [Related]
17. Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.
Richardson PG; Hofmeister CC; Raje NS; Siegel DS; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J; Doss D; Zaki MH; Bensmaine A; Herring J; Li Y; Watkins L; Chen MS; Anderson KC
Leukemia; 2017 Dec; 31(12):2695-2701. PubMed ID: 28642620
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus infection and risk of multiple myeloma: Evidence from a meta-analysis based on 17 case-control studies.
Li Y; Li Y; Zhang L; Li W
J Viral Hepat; 2017 Dec; 24(12):1151-1159. PubMed ID: 28656736
[TBL] [Abstract][Full Text] [Related]
19. Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma.
Voorhees PM; Gasparetto C; Moore DT; Winans D; Orlowski RZ; Hurd DD
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17(7):424-432. PubMed ID: 28655599
[TBL] [Abstract][Full Text] [Related]
20. Autologous Stem Cell Transplantation in Patients With Multiple Myeloma: An Activity-based Costing Analysis, Comparing a Total Inpatient Model Versus an Early Discharge Model.
Martino M; Console G; Russo L; Meliado' A; Meliambro N; Moscato T; Irrera G; Messina G; Pontari A; Morabito F
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):506-512. PubMed ID: 28647402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
